Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2022
- First clinical trial with HDP-101 in multiple myeloma on track, third patient cohort started
- Significant progress achieved in partner projects and further ATAC® agreements signed with Chiome Bioscience and Takeda
- Rights issue with proceeds of approximately EUR 80 million conducted in August; strategic partnership with Huadong Medicine thus completed
- Significantly increased sales revenue due to license payment from Huadong led, among other things, to adjusted guidance
Heidelberg Pharma AG today reported on the development of its Antibody Targeted Amanitin Conjugate technology as well as on the Group’s financial figures for the first nine months of fiscal year 2022 (1 December 2021 – 31 August 2022).